177 related articles for article (PubMed ID: 36291936)
1. Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring.
Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; Cleven AHG; van Wezel T; van Eijk R; Ruano D; Veelken JHH; Tensen CP; Neelis KJ; Daniels LA; Hauben E; Woei-A-Jin FJSHS; Busschots AMA; Vermeer MH; Vermaat JSP
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291936
[TBL] [Abstract][Full Text] [Related]
2. Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.
Lucioni M; Pescia C; Bonometti A; Fraticelli S; Moltrasio C; Ramponi A; Riboni R; Roccio S; Ferrario G; Arcaini L; Goteri G; Berti E; Paulli M
Hum Pathol; 2021 May; 111():1-9. PubMed ID: 33548250
[TBL] [Abstract][Full Text] [Related]
3. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas.
Uccella S; Goteri G; Maiorana A; Donati V; Tibiletti MG; Magnoli F; Facchi S; Merchiori D; Morsia E; Papotti R; Bettelli S; Forti E; Galimberti S; Rupoli S; Filosa A; Dardanis D; Bomben R; Braglia L; Pozzi S; Sacchi S
Hum Pathol; 2023 Jun; 136():44-55. PubMed ID: 36997030
[TBL] [Abstract][Full Text] [Related]
5. Indurated Plaques on the Legs: Think Lymphoma.
Watts-Santos A; Cuellar-Barboza A; Ramos-Cavazos CJ; Villarreal-Martinez A; Ocampo-Candiani J; Herz-Ruelas ME
Acta Dermatovenerol Croat; 2021 Jul; 29(2):114-115. PubMed ID: 34477080
[TBL] [Abstract][Full Text] [Related]
6. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; van Wezel T; van Eijk R; Ruano D; Tensen CP; Hauben E; Woei-A-Jin FJSH; Busschots AM; van den Berg A; Diepstra A; Vermeer MH; Vermaat JSP
Virchows Arch; 2022 Mar; 480(3):667-675. PubMed ID: 35028710
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM; Ansell SM; Villasboas JC; Bennani NN; Wang Y; Habermann TM; Thanarajasingam G; Lester SC; Macon W; Inwards DJ; Porrata LF; Micallef IN; Witzig TE; Thompson CA; Johnston PB; Nowakowski GS; Lin Y; Paludo J
Hematol Oncol; 2021 Dec; 39(5):658-663. PubMed ID: 34453851
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.
Paulli M; Lucioni M; Maffi A; Croci GA; Nicola M; Berti E
G Ital Dermatol Venereol; 2012 Dec; 147(6):589-602. PubMed ID: 23149705
[TBL] [Abstract][Full Text] [Related]
9. Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.
Mareschal S; Pham-Ledard A; Viailly PJ; Dubois S; Bertrand P; Maingonnat C; Fontanilles M; Bohers E; Ruminy P; Tournier I; Courville P; Lenormand B; Duval AB; Andrieu E; Verneuil L; Vergier B; Tilly H; Joly P; Frebourg T; Beylot-Barry M; Merlio JP; Jardin F
J Invest Dermatol; 2017 Sep; 137(9):1984-1994. PubMed ID: 28479318
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response.
Graham PM; Richardson AS; Schapiro BL; Saunders MD; Stewart DM
JAAD Case Rep; 2018 May; 4(4):305-309. PubMed ID: 29693055
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.
Al Dhafiri M; Sicre de Fontbrune F; Marinho E; Deschamps L; Di-Lucca J; Crickx B; Descamps V
Clin Case Rep; 2019 May; 7(5):964-967. PubMed ID: 31110725
[TBL] [Abstract][Full Text] [Related]
12. Bone involvement in primary cutaneous diffuse large B-cell lymphoma, leg-type.
Laurent C; Ram-Wolff C; Ingen-Housz-Oro S; Beylot-Barry M; Barete S; Saillard C; Dupuy A; Bagot M; Adamski H
Clin Exp Dermatol; 2023 Feb; 48(2):116-120. PubMed ID: 36730524
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.
Lucioni M; Berti E; Arcaini L; Croci GA; Maffi A; Klersy C; Goteri G; Tomasini C; Quaglino P; Riboni R; Arra M; Dallera E; Grandi V; Alaibac M; Ramponi A; Rattotti S; Cabras MG; Franceschetti S; Fraternali-Orcioni G; Zerbinati N; Onida F; Ascani S; Fierro MT; Rupoli S; Gambacorta M; Zinzani PL; Pimpinelli N; Santucci M; Paulli M
Cancer Med; 2016 Oct; 5(10):2740-2755. PubMed ID: 27665744
[TBL] [Abstract][Full Text] [Related]
14. A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N; Martínez-Madueño F; Caballé B; Badia J; Blanes M; Bujanda DA; Calvo V; Gómez Codina J; Blanco CQ; Espinosa P; Lavernia J; Arroyo FRG; Risueño MG; Llorca C; Cumeras R; Pulla MP; Gumà J
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473391
[TBL] [Abstract][Full Text] [Related]
15. Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Gupta E; Accurso J; Sluzevich J; Menke DM; Tun HW
Rare Tumors; 2015 Dec; 7(4):6067. PubMed ID: 26788279
[TBL] [Abstract][Full Text] [Related]
16. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.
Grange F; Joly P; Barbe C; Bagot M; Dalle S; Ingen-Housz-Oro S; Maubec E; D'Incan M; Ram-Wolff C; Dalac S; Templier I; Esteve E; Quereux G; Machet L; Leduc M; Dereure O; Laroche L; Saiag P; Vergier B; Beylot-Barry M
JAMA Dermatol; 2014 May; 150(5):535-41. PubMed ID: 24647650
[TBL] [Abstract][Full Text] [Related]
17. CD5+ Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Presenting as an Asymptomatic Nodule.
Xiao A; Beatty CJ; Choudhary S; Akilov OE
Hematol Rep; 2023 Sep; 15(3):513-517. PubMed ID: 37754668
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
Fox LC; Yannakou CK; Ryland G; Lade S; Dickinson M; Campbell BA; Prince HM
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899297
[TBL] [Abstract][Full Text] [Related]
19. Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report.
Zoli S; Pellegrini C; Casadei B; Broccoli A; Argnani L; Nanni L; Stefoni V; Zinzani PL
Chemotherapy; 2024; 69(1):23-26. PubMed ID: 37913761
[TBL] [Abstract][Full Text] [Related]
20. F-18 FDG PET/CT in staging and response assessment of primary cutaneous diffuse large B-cell lymphoma (leg type).
Datta D; Pandey RR; Kumar R; Sharma R; Vedant D
Eur J Hybrid Imaging; 2023 Aug; 7(1):15. PubMed ID: 37605015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
